Recombinant Human Erythropoietin: Factors to Consider in Cost-Benefit Analysis
- 1 January 1991
- journal article
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 17 (1) , 86-92
- https://doi.org/10.1016/s0272-6386(12)80258-7
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group.BMJ, 1990
- The Quality of Life of Hemodialysis Recipients Treated With Recombinant Human ErythropoietinJAMA, 1990
- Treatment of the Anemia of Progressive Renal Failure with Recombinant Human ErythropoietinNew England Journal of Medicine, 1989
- Recombinant Human Erythropoietin Treatment in Pre-Dialysis PatientsAnnals of Internal Medicine, 1989
- Posttransfusion hepatitis in Toronto, CanadaGastroenterology, 1988
- Special Report: Transfusion RisksAmerican Journal of Clinical Pathology, 1987
- Transfusion-Associated Hepatitis and AIDSNew England Journal of Medicine, 1987
- Correction of the Anemia of End-Stage Renal Disease with Recombinant Human ErythropoietinNew England Journal of Medicine, 1987
- Should Donor Blood Be Screened for Elevated Alanine Aminotransferase Levels?JAMA, 1984
- Physical Activity and Employment Status of Patients on Maintenance DialysisNew England Journal of Medicine, 1981